article thumbnail

Top Life Science News and Trends in 2023 at Xtalks

XTalks

In 2023, there were significant advancements and notable trends in the life sciences. Xtalks compiled a list of its top life science news and trends of 2023, which provided readers with the latest developments, information and expert insights across life science industries, including pharma, biotech and medical device.

article thumbnail

How AI/ML-based PHI & PII redaction solutions can help life sciences organizations

Cloudbyz

In today’s digital age, life sciences organizations are collecting, storing, and processing vast amounts of sensitive data, including personally identifiable information (PII) and protected health information (PHI). As such, it’s becoming increasingly challenging for organizations to manage and secure this data.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

A Message to Pharma CIOs: Optimizing Salesforce Improves Security and Compliance

pharmaphorum

However, issues like compliance, governance and security often are. That’s why CIOs and CTOs working within the life sciences industry need to include Salesforce org management as a key component of their standard operating procedures. This will help ensure consistency and compliance across the entire enterprise. .

article thumbnail

Thirty years of the Patented Medicines (Notice of Compliance) Regulations

Pharma in Brief

This year marks the 30-year anniversary of the Patented Medicines (Notice of Compliance) Regulations ( Regulations ), introduced in 1993 to prevent patent infringement by linking the regulatory approval of generic or biosimilar drugs with the patent rights of innovators. 3d) 209 (FCA), at paras. 5] Merck Frosst Canada Inc.

article thumbnail

Data protection upheld for subsequently approved combination drugs containing new chemical entities: Federal Court finds Minister of Health’s decision to deny generic ANDS filing is reasonable

Pharma in Brief

The Decision refused to accept Natco’s ANDS filing using Gilead Sciences Canada Inc.’s DESCOVY contains a combination of tenofovir alafenamide ( TAF ) hemifumarate and emtricitabine. Because DESCOVY contains TAF, it benefits from the same data protection term granted to GENVOYA. Background. Minister of Health’s Decision.

article thumbnail

Tiziana Life Sciences announces collaboration with Parexel Biotech to conduct phase 1b/2 clinical trial in patients with Crohn’s Disease

The Pharma Data

Weiner, chairman of the scientific advisory board of Tiziana Life Sciences, commented: “We understand that this will be the first-ever study with ‘take-home’ capsules of any mAb for immunotherapies for human diseases. However, severe toxicities and poor patient compliance limit the long-term use for intravenous immunotherapies.

article thumbnail

Is the proposed Data Protection and Digital Information Bill fit for purpose?

pharmaphorum

Instead, organisations will designate a senior employee to oversee an organisation’s compliance with data protection rules. It contains my own views and opinions and doesn’t constitute legal advice. Wendy Lloyd Godwin is the founder of Life Science Law. This Article is for information purposes only. About the author.